IGC Pharma Expands CALMA Phase 2 Trial for Alzheimer's Agitation Treatment with New Oklahoma Site
Key Insights
IGC Pharma (search) has expanded its Phase 2 CALMA trial evaluating IGC-AD1 for Alzheimer's agitation by adding Lynn Health Science Institute (search) in Oklahoma City as a new clinical site.
The randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of the cannabinoid-based therapy in reducing agitation symptoms in Alzheimer's patients.
Dr. Carl Griffin will serve as Principal Investigator at the new site, which is now actively enrolling participants for the trial targeting one of Alzheimer's most challenging symptoms.
IGC Pharma (search) has expanded its ongoing Phase 2 clinical trial for IGC-AD1, a cannabinoid-based investigational therapy for treating agitation in Alzheimer's disease (search) patients, by adding the Lynn Health Science Institute (search) (LHSI) in Oklahoma City, Oklahoma as a new clinical site.
Dr. Carl Griffin, MD, will serve as the Principal Investigator for the Oklahoma site, bringing extensive experience in conducting clinical trials and a commitment to improving outcomes for patients with neurodegenerative diseases. The team at LHSI will begin recruiting eligible patients immediately.
"Expanding our clinical footprint to Oklahoma represents another important step toward reaching more patients and families affected by this devastating condition," said Ram Mukunda, CEO of IGC Pharma (search). "We are pleased to welcome Dr. Griffin and the Lynn Health Science Institute (search) to the CALMA trial and look forward to their contributions in advancing our mission."
CALMA Trial Design and Objectives
The CALMA trial is a randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the safety and efficacy of IGC-AD1 in reducing agitation in individuals diagnosed with Alzheimer's disease (search). Agitation represents one of the most challenging and disruptive symptoms associated with Alzheimer's, often leading to earlier institutionalization and significant caregiver stress.
Lynn Health Science Institute (search) is now actively enrolling participants in the expanded trial. The Oklahoma City facility brings over two decades of experience in clinical research and is recognized for conducting Phase I-IV trials across multiple therapeutic areas with a commitment to patient care, data integrity, and research excellence.
IGC Pharma's Alzheimer's Pipeline
IGC Pharma (search) is a clinical-stage biotechnology company leveraging artificial intelligence to develop innovative treatments for Alzheimer's and metabolic disorders. Beyond IGC-AD1, the company's pipeline includes TGR-63, which targets amyloid plaques (search), and early-stage programs focused on neurodegeneration, tau proteins (search), and metabolic dysfunctions.
The company integrates AI technology to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings supporting its research efforts, IGC Pharma (search) is positioning itself as an innovator in breakthrough therapies for neurodegenerative conditions.
Clinical Site Expansion Strategy
The addition of LHSI represents IGC Pharma (search)'s continued effort to expand patient access and accelerate enrollment in the CALMA trial. The Lynn Health Science Institute (search)'s established infrastructure and experienced research team are expected to contribute significantly to the trial's progress and data collection efforts.
For patients and families interested in participating in the CALMA trial at the Oklahoma site, enrollment information is available through Clinical Research Coordinator Mikayla Dade at MDADE@LHSI.NET or by calling (405) 602-3939 ext. 106.